SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

Korábbi kezelés

• Any prior anti-cancer therapy (chemotherapy, radiotherapy, targeted, endocrine, etc.); radical radiotherapy ≤ 4 weeks or palliative radiotherapy ≤ 2 weeks before first dose.
• Concomitant anti-cancer therapy of any kind.
• Participation in another drug trial ≤ 4 weeks before enrolment.
• Systemic immunosuppressive therapy (e.g., \> 10 mg/day prednisone equivalent) ≤ 2 weeks before first dose (nasal/inhaled corticosteroids allowed).
• Live or attenuated vaccines ≤ 4 weeks before first dose.
• Major non-breast surgery ≤ 4 weeks before first dose or not fully recovered.
• Immunodeficiency (HIV positive, congenital/secondary), prior organ transplant.
• Interstitial lung disease or any moderate-severe pulmonary disorder that may interfere with drug-related lung toxicity assessment: idiopathic pulmonary fibrosis, organizing pneumonia/bronchiolitis obliterans, pulmonary embolism, severe asthma/COPD, restrictive/obstructive defects, autoimmune/connective-tissue lung involvement, prior pneumonectomy.
• Any severe concomitant condition jeopardizing patient safety or compliance (e.g., uncontrolled hypertension, diabetes, active infection) or significant neurologic/psychiatric disorder (epilepsy, dementia) that, in the investigator's opinion, renders

Más betegség

• Breast cancer not confirmed by histopathology.
• Bilateral, inflammatory, or occult breast cancer.
• Other malignancies within 5 years (except cured basal-cell skin cancer or cervical carcinoma in situ).
• Active autoimmune disease or history of recurrent autoimmunity (e.g., autoimmune hepatitis, uveitis, colitis, hypophysitis, vasculitis, nephritis, hyper/hypothyroidism except stable hormone replacement). Controlled vitiligo, psoriasis, alopecia, insulin-dependent type 1 diabetes, or childhood asthma in complete remission allowed. Asthma requiring bronchodilators excluded.
• Hereditary/acquired bleeding or thrombotic diatheses (e.g., hemophilia, coagulopathy).
• Known hypersensitivity to study drugs or excipients.

Laborértékek

• Uncontrolled or significant cardiovascular/cerebrovascular disease, including within 6 months: NYHA III/IV heart failure, MI, stroke (except lacunar), pulmonary embolism, unstable angina, significant arrhythmia; cardiomyopathies; QTc \> 470 ms (Fridericia, female), 2nd/3rd degree AV block, atrial fibrillation ≥ EHRA 2b, uncontrolled hypertension.
• Active hepatitis B (HBsAg+ and HBV DNA ≥ 500 IU/mL), hepatitis C (anti-HCV+ and HCV RNA \> ULN), cirrhosis, or severe infection requiring antibiotics/antivirals/antifungals.

Egyéb

• Pregnant or lactating women; women of child-bearing potential with positive baseline pregnancy test or unwilling to use effective contraception throughout the study.

• Female, aged 18-70 years at the time of informed consent.
• Histologically confirmed invasive breast cancer, with no prior systemic anti-cancer therapy.
• Pathologically documented HR-positive (ER ≥ 1% and/or PR ≥ 1%) and HER2-positive disease, per the 2018 ASCO-CAP guidelines: IHC 3+ or IHC 2+ with ISH ratio ≥ 2.0.
• Clinical stage II-III (cT2-cT4 or cN+, cM0) per the 8th edition of the AJCC Cancer Staging Manual.
• At least one measurable lesion per RECIST v1.1 criteria.
• ECOG performance status 0-1.
• Estimated life expectancy of ≥ 12 months.
• Adequate organ function within 14 days prior to the first dose (without transfusion or growth factor support):
  • Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; platelets ≥ 100 × 10⁹/L; hemoglobin (Hb) ≥ 90 g/L
  • Albumin ≥ 3.0 g/dL; total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); alanine transaminase (ALT)/aspartate transaminase (AST) ≤ 2.5 × ULN; alkaline phosphatase (ALP) ≤ 2.5 × ULN; blood urea nitrogen (BUN) and creatinine ≤ 1.5 × ULN, or creatinine clearance (CrCl) ≥ 60 mL/min (per Cockcroft-Gault formula)
  • Prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN
  • Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiography
  • Fridericia-corrected QT interval (QTcF) ≤ 470 ms
• Premenopausal women with reproductive potential must have a negative serum β-human chorionic gonadotropin (β-hCG) test within 7 days before treatment, use effective barrier contraception throughout the study period and for 6 months after the last dose, and not be breastfeeding.
• Provision of signed written informed consent; willingness to comply with all study visits and procedures.